CHRU De Nancy

The department conducts studies on cardiovascular health, aiming to test new therapies and improve patient outcomes.

• Acute Coronary Syndrome
• Acute myocardial infarction
• Chronic Heart Failure With Reduced Ejection Fraction
• Uncontrolled Hypertension in chronic kidney disease
• Pulmonary Arterial Hypertension

Ongoing trials evaluate novel anticoagulants, blood‑pressure optimization strategies, and agents that reduce cardiovascular events and heart‑failure hospitalizations.

Research focuses on gastro‑intestinal and liver cancers, exploring innovative treatment combinations to extend survival.

• Hepatocellular Carcinoma
• Advanced Hepatocellular Carcinoma
• Biliary tract carcinoma
• Colon carcinoma
• Small bowel adenocarcinoma

Studies assess immunotherapy, targeted agents, and neo‑adjuvant chemotherapy protocols to improve disease‑free survival.

Trials address immune‑mediated and autoimmune disorders, seeking safer, more effective therapeutic options.

• Ulcerative Colitis
• Crohn's disease
• Food allergy
• Non‑infectious uveitis
• Binge eating disorder

Research evaluates biologics, oral small‑molecule agents, and dietary interventions to control inflammation and improve quality of life.

The site investigates blood‑related cancers and bone‑marrow failures, aiming to raise remission rates and long‑term survival.

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Diffuse Large B‑Cell Lymphoma
• Follicular lymphoma
• Marginal Zone Lymphoma

Studies compare novel kinase inhibitors, bispecific antibodies, and reduced‑intensity conditioning regimens for stem‑cell transplantation.

Clinical work targets metabolic liver disease and related metabolic disorders, testing agents that reverse tissue damage.

• Non‑Alcoholic Steatohepatitis (NASH)
• Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
• Fibrosis
• Diabetes‑related complications

Trials assess drugs that improve liver histology, reduce fibrosis, and enhance overall metabolic health.

Studies aim to improve outcomes for lung‑related conditions, including rare progressive diseases.

• Interstitial lung disease
• Pulmonary arterial hypertension
• Acute respiratory complications

Investigations include targeted therapies and functional measures such as exercise capacity to assess efficacy.